Literature DB >> 3610019

Circulating lipid A antibodies and their relationship to different clinical conditions of patients with Crohn's disease.

W Kruis, P Schussler, M Weinzierl.   

Abstract

Endotoxins have been suggested to be a factor in the pathophysiology of Crohn's disease (CD). We determined circulating antibodies against lipid A, a component common to endotoxins of gram-negative bacteria. Lipid A antibody titers in 91 patients with CD were significantly higher than in 56 patients with ulcerative colitis and 68 healthy subjects. In active CD lipid A antibodies were higher than in quiescent CD and markedly elevated titers of lipid A antibodies were associated with a severe course of CD. Duration, extent and localisation of CD showed no relationship to antibody titers against lipid A. Patients with prior bowel resection had a tendency towards lower antibody titers in comparison with non-operated patients. After total removal of inflamed bowel tissue, lipid A antibodies frequently disappeared. Medical therapy had different effects: prednisone and sulfasalazine did not influence antibody formation against lipid A, whereas antibody titers dropped significantly after therapy with ampicillin. These results confirm elevated circulating lipid A antibodies in patients with CD. Although it remains unclear whether lipid A antibodies are only an epiphenomenon in CD, on the basis of this clinical study further evidence is provided for the involvement of lipid A in the pathophysiology of CD.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3610019

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  1 in total

1.  Serum anti-flagellin and anti-lipopolysaccharide immunoglobulins as predictors of linear growth faltering in Pakistani infants at risk for environmental enteric dysfunction.

Authors:  Sana Syed; Najeeha T Iqbal; Kamran Sadiq; Jennie Z Ma; Tauseef Akhund; Wenjun Xin; Sean R Moore; Enju Liu; Shahida Qureshi; Kerri Gosselin; Andrew Gewirtz; Christopher P Duggan; S Asad Ali
Journal:  PLoS One       Date:  2018-03-06       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.